ZIVO Bioscience Collaborates with University of Delaware
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a trailblazer in biotech and agricultural technology, has announced plans for a collaborative study with the University of Delaware. This initiative seeks to deepen the understanding and effectiveness of ZIVO's unique active ingredients in combating Low Pathogenicity Avian Influenza (LPAI) within poultry populations.
Prior Study Success and Future Goals
Previously, ZIVO’s partnership with the University yielded promising results, showcasing a notable decrease in viral shedding and delaying disease transmission among the treated birds. The upcoming research is geared towards refining treatment formulations and protocols to maximize the application of ZIVO’s proprietary ingredients in practical poultry production settings.
Research Impacts on Animal Health
With the backdrop of encouraging results from past studies focusing on avian influenza and coccidiosis, ZIVO has attracted considerable attention from major global players in animal health. These companies are eager to find innovative, non-antibiotic solutions to address the challenges of disease transmission in poultry. This interest highlights the growing demand for natural, algal-derived products that can bolster poultry health and productivity.
The Expertise of University of Delaware
The University of Delaware is renowned for its significant contributions to animal science research. John Payne, Chairman and CEO of ZIVO Bioscience, expressed enthusiasm about continuing their collaboration, emphasizing its importance in advancing the understanding of their active ingredients' roles against avian influenza. "The interest from key animal health companies further affirms our commitment to providing sustainable, effective solutions that meet the needs of the poultry industry at competitive prices," he stated.
Future Intentions and Research Directions
This latest study marks just the beginning of what ZIVO anticipates will be a series of investigations focused on evaluating the effectiveness of its products against various applications of avian influenza. By harnessing the active components from its proprietary algal cultures, the company aims to innovate effective and natural alternatives to conventional treatments. This endeavor addresses the pressing concerns of cost and drug resistance that currently challenge the animal health landscape.
About ZIVO Bioscience
ZIVO Bioscience, Inc. is dedicated to research and development with a robust intellectual property portfolio that includes proprietary algal and bacterial strains, bioactive molecules, and cultivation techniques. The company continues to push the boundaries of science to improve both human and animal health outcomes through its innovative products. For more insights into their offerings and research, please visit their website.
Frequently Asked Questions
What is the focus of the new study by ZIVO Bioscience?
The study aims to evaluate the effectiveness of ZIVO's active ingredients in combating Low Pathogenicity Avian Influenza in poultry populations.
How successful was ZIVO's previous study?
The previous study significantly reduced viral shedding and delayed transmission of the disease among treated birds.
What is ZIVO’s approach to animal health?
ZIVO is committed to providing non-antibiotic solutions that improve poultry health and productivity while addressing cost and drug resistance challenges.
Why is the University of Delaware important to this research?
The University is known for its expertise in animal science and strengthens ZIVO's research capabilities through its collaboration.
What does ZIVO hope to achieve with this ongoing research?
ZIVO aims to continually refine its products and develop natural alternatives to traditional treatments, positioning themselves as leaders in innovative animal health solutions.
